Clinical trials: Ophthalmology
Ophthalmology, Photorefractive Keratectomy ("PRK")
Ocular Bandage Gel (OBG) Pivotal Trial in Patients Undergoing Photorefractive Keratectomy ("PRK")
Prospective, randomized, masked (reading center), controlled pivotal study of Ocular Bandage Gel (OBG) vs. a bandage contact lens (BCL) in subjects who have undergone bilateral photorefractive keratectomy (PRK).
- Conditions
- Ophthalmology, Photorefractive Keratectomy ("PRK"), Laser Assisted Surgery, Refractive Surgery
- Trial name
- NCT03938883
- Testing
- Ocular Bandage Gel (OBG), Bandage Contact Lens (BCL)
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Cerebrotendinous Xanthomatosis (CTX)
Cerebrotendinous Xanthomatosis (CTX) Prevalence Study
Iiopathic bilateral cataracts occur in many children with Cerebrotendinous Xanthomatosis (CTX) so the opportunity to use contact with health care providers in connection with pediatric cataract evaluation and treatment is a…
- Trial name
- NCT02638220
- Where
- 44 sites in United States
- Volunteers
- 442 people
- Sponsor
- Travere Therapeutics, Inc.
Anterior Uveitis
Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis
The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate…
- Trial name
- NCT01505088
- Testing
- 40 mg/mL Dexamethasone phosphate ophthalmic solution, Prednisolone Acetate (1%) Eyedrops, 100 mM sodium citrate buffer solution
- Where
- 39 sites in United States
- Volunteers
- 193 people
- Sponsor
- Eyegate Pharmaceuticals, Inc.
Specialist Referral: Neurology, Specialist Referral: Ophthalmology
A Study to Characterize Access to Specialty Care Received by American Indians/Alaska Natives
This is an observational study to define current care pathways for American Indian or Alaska Native patients who require specialty care and potential feasibility of conducting clinical research within the existing framework.
- Conditions
- Specialist Referral: Neurology, Specialist Referral: Ophthalmology, Specialist Referral: Oncology
- Trial name
- CATORI (NCT05624788)
- Testing
- No Intervention
- Where
- 2 sites in United States
- Volunteers
- 84 people
- Sponsor
- Genentech, Inc.
Ophthalmology, Macular Degeneration
Study to Assess the Effectiveness of Existing Anti vascUlar Endothelial Growth Factor (Anti VEGF) in Patients With Wet Age-related Macular Degeneration (wAMD) (AURA)
Retrospective, non-interventional, observational multi-center field study. Patients diagnosed with wet Age-related macular degeneration (wAMD) and having started treatment with ranibizumab between January 1, 2009 and August 31…
- Trial name
- AURA (NCT01447043)
- Testing
- Ranibizumab
- Where
- 10 sites in Australia, Canada and 8 more
- Volunteers
- 2,609 people
- Sponsor
- Bayer
Allergic Conjunctivitis
Evaluation of Efficacy and Safety of an Anti-Allergy Drug With a Contact Lens in the Treatment of Allergic Conjunctivitis
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy drug with a contact lens compared to placebo in preventing ocular itching associated with allergic conjunctivitis
- Trial name
- NCT00445874
- Testing
- Ketotifen with a Contact Lens (no generic name)
- Where
- 7 sites in United States
- Volunteers
- 120 people
- Sponsor
- Vistakon Pharmaceuticals
Blepharoconjunctivitis
Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis
The purpose of this study is to determine if AzaSite Plus is effective and safe for the treatment of blepharoconjunctivitis compared to AzaSite alone and Dexamethasone alone.
- Trial name
- NCT00578955
- Testing
- 1% Azithromycin and 0.1% Dexamethasone, 1% Azithromycin, 0.1% Dexamethasone
- Volunteers
- 417 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Uveal Melanoma
Neoadjuvant Darovasertib in Primary Uveal Melanoma
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
- Trial name
- NCT07015190
- Testing
- Darovasertib, Primary Local Therapy
- Where
- 94 sites in United States, Australia and 19 more
- Volunteers
- 520 people
- Sponsor
- IDEAYA Biosciences
Age-related Macular Degeneration
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
To define what procedures were used for the diagnosis and monitoring of the treatment age-related macular degeneration (AMD). What is the effect of the Macugen, compliance with Macugen treatment, safety profile of Macugen, final…
- Trial name
- NCT00787319
- Testing
- no intervention
- Where
- 11 sites in Czechia
- Volunteers
- 108 people
- Sponsor
- Pfizer
Eye Diseases
Dafilon® Suture Material in Patients Undergoing Ophthalmic Surgery
This is an observational, retrospective postmarket clinical follow-up study and includes all patients who underwent any ophthalmic surgery using Dafilon® suture in the selected centres between 2018 and 2020, therefore no sample…
- Trial name
- OPHTHADA (NCT05968443)
- Testing
- ophthalmic surgery
- Where
- Malaysia
- Volunteers
- 200 people
- Sponsor
- Aesculap AG
Healthy Subjects
A Phase 1, Open-Label, 10 Day Safety Study
This is a Phase 1 open-label study in healthy volunteers who will receive oral 200 mg TR 701 FA once daily for 10 days and will include ophthalmologic and neurologic assessments.
- Trial name
- NCT01623401
- Testing
- TR-701 FA
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Malaria, Vivax
Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)
The study aims to provide evidence of retinal safety to support the use of tafenoquine as a potential single dose radical cure treatment for patients with Plasmodium vivax (P.
- Trial name
- NCT02658435
- Testing
- Tafenoquine 150 mg
- Where
- 3 sites in United States
- Volunteers
- 486 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Myopia
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Moderate to High Myopia
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of moderate to high myopia (nearsightedness), when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
- Trial name
- NCT00762541
- Testing
- MEL 80 Treatment of High Myopia
- Where
- 5 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec, Inc.
Ophthalmology, Macular Edema
Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy
POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.
- Conditions
- Ophthalmology, Macular Edema, Macular Degeneration
- Trial name
- POLARIS (NCT01771081)
- Testing
- Ranibizumab (or other DME treatment)
- Where
- 8 sites in France, Germany and 6 more
- Volunteers
- 911 people
- Sponsor
- Bayer
Diabetic Macular Edema
A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®) for the treatment of Diabetic Macular Edema…
- Trial name
- NCT02281292
- Testing
- LKA651 ophthalmic solution, Ranibizumab ophthalmic solution
- Sponsor
- Alcon Research
Uveal Melanoma
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma
- Trial name
- NCT05907954
- Testing
- Darovasertib
- Where
- 18 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- IDEAYA Biosciences
Macular Degeneration, Diabetic Retinopathy (DR)
Artificial Intelligence-assisted Diagnosis in Ophthalmology
This is a retrospective, multicenter, observational study designed to develop and validate an artificial intelligence (AI) system capable of detecting and classifying major ophthalmic diseases (glaucoma, cataract, diabetic…
- Conditions
- Macular Degeneration, Diabetic Retinopathy (DR), Glaucoma, Keratoconus
- Trial name
- AI-OPHTH-CR (NCT07497815)
- Testing
- No interventions
- Where
- 2 sites in Costa Rica
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Marisse Masis-Solano
Mixed Astigmatism
Study of the MEL 80 Excimer Laser Using LASIK in the Treatment of Mixed Astigmatism
The purpose of this study is to determine whether the MEL 80 Excimer Laser is effective in the treatment of mixed astigmatism up to 6.0 D, when used as part of the Laser In Situ Keratomileusis (LASIK) procedure.
- Trial name
- NCT00761826
- Testing
- MEL 80 Mixed Astigmatism Treatment
- Where
- 5 sites in United States
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Carl Zeiss Meditec, Inc.
Cataract
Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-2)
Cataract surgery is one of the most common surgical procedures performed worldwide. In fact, in 2017, 3.8 million cataracts procedures were performed in the US.
- Trial name
- CLOSE-2 (NCT04249076)
- Testing
- Clobetasol Propionate, Vehicle
- Where
- 18 sites in United States
- Volunteers
- 215 people
- Sponsor
- Salvat
Optic Nerve Diseases
Study to Evaluate Eye Function in Patients Taking Linezolid for Six Weeks or Greater
To understand and characterize the effects of linezolid on the optic nerve by observing and following patients who have been treated with linezolid for six weeks or longer for the development of signs or symptoms of visual…
- Trial name
- NCT00359632
- Testing
- Zyvox - linezolid, Matched control
- Where
- 12 sites in United States, Italy and 1 more
- Volunteers
- 34 people
- Sponsor
- Pfizer